Hydrocortisone Acetate
Action and use
Corticosteroid.
Preparations
Clotrimazole and Hydrocortisone Acetate Cream
Gentamicin and Hydrocortisone Acetate Ear Drops
Hydrocortisone Acetate and Neomycin Ear Drops
Hydrocortisone Acetate and Neomycin Eye Drops
Hydrocortisone Acetate and Neomycin Eye Ointment
Hydrocortisone Acetate Injection
Hydrocortisone Acetate Ointment
Hydrocortisone Acetate Oral Suspension
Miconazole and Hydrocortisone Acetate Cream
Ph Eur
DEFINITION
11β,17-Dihydroxy-3,20-dioxopregn-4-en-21-yl acetate.
Content
97.0 per cent to 102.0 per cent (dried substance).
CHARACTERS
Appearance
White or almost white, crystalline powder.
Solubility
Practically insoluble in water, slightly soluble in anhydrous ethanol and in methylene chloride.
IDENTIFICATION
First identification: A, B
Second identification: C, D, E
Comparisonhydrocortisone acetate CRS.
Results The principal peak in the chromatogram obtained with test solution (b) is similar in retention time and size to the principal peak in the chromatogram obtained with reference solution (d).
Test solution (a) Dissolve 25 mg of the substance to be examined in methanol R and dilute to 5 mL with the same solvent (solution A). Dilute 2 mL of the solution to 10 mL with methylene chloride R.
Test solution (b) Transfer 2 mL of solution A to a 15 mL glass tube with a ground-glass stopper or a polytetrafluoroethylene cap. Add 10 mL of saturated methanolic potassium hydrogen carbonate solution R and immediately pass a stream of nitrogen R briskly through the solution for 5 min. Stopper the tube. Heat in a water-bath at 45 °C protected from light for 2 h 30 min. Allow to cool.
Reference solution (a) Dissolve 25 mg of hydrocortisone acetate CRS in methanol R and dilute to 5 mL with the same solvent (solution B). Dilute 2 mL of the solution to 10 mL with methylene chloride R.
Reference solution (b) Transfer 2 mL of solution B to a 15 mL glass tube with a ground-glass stopper or a polytetrafluoroethylene cap. Add 10 mL of saturated methanolic potassium hydrogen carbonate solution R and immediately pass a stream of nitrogen R briskly through the solution for 5 min. Stopper the tube. Heat in a water-bath at 45 °C protected from light for 2 h 30 min. Allow to cool.
PlateTLC silica gel F254 plate R.
Mobile phase Add a mixture of 1.2 volumes of water R and 8 volumes of methanol R to a mixture of 15 volumes of ether R and 77 volumes of methylene chloride R.
Application 5 µL.
Development Over 3/4 of the plate.
Drying In air.
Detection A Examine in ultraviolet light at 254 nm.
Results A The principal spot in each of the chromatograms obtained with the test solutions is similar in position and size to the principal spot in the chromatogram obtained with the corresponding reference solution.
Detection B Spray with alcoholic solution of sulfuric acid R and heat at 120 °C for 10 min or until the spots appear and allow to cool; examine in daylight and in ultraviolet light at 365 nm.
Results B The principal spot in each of the chromatograms obtained with the test solutions is similar in position, colour in daylight, fluorescence in ultraviolet light at 365 nm and size to the principal spot in the chromatogram obtained with the corresponding reference solution. The principal spots in the chromatograms obtained with test solution (b) and reference solution (b) have an RF value distinctly lower than that of the principal spots in the chromatograms obtained with test solution (a) and reference solution (a).
TESTS
Specific optical rotation (2.2.7)
+ 158 to + 167 (dried substance).
Dissolve 0.250 g in dioxan R and dilute to 25.0 mL with the same solvent.
Related substances
Liquid chromatography (2.2.29).
Solvent mixtureacetic acid R, water R, methanol R (1:10:90 V/V/V).
Test solution (a) Dissolve 25.0 mg of the substance to be examined in the solvent mixture and dilute to 25.0 mL with the solvent mixture.
Test solution (b) Dilute 1.0 mL of test solution (a) to 10.0 mL with the solvent mixture.
Reference solution (a) Dissolve 2 mg of hydrocortisone acetate CRS and 2 mg of prednisolone acetate CRS (impurity C) in the solvent mixture and dilute to 100.0 mL with the solvent mixture.
Reference solution (b) Dilute 1.0 mL of test solution (a) to 100.0 mL with the solvent mixture. Dilute 1.0 mL of this solution to 10.0 mL with the solvent mixture.
Reference solution (c) Dissolve 5 mg of hydrocortisone acetate for peak identification CRS (containing impurities A, B, D, E and G) in 2.0 mL of the solvent mixture.
Reference solution (d) Dissolve 25.0 mg of hydrocortisone acetate CRS in the solvent mixture and dilute to 25.0 mL with the solvent mixture. Dilute 1.0 mL of the solution to 10.0 mL with the solvent mixture.
Mobile phase Mix 400 mL of acetonitrile R with 550 mL of water R and allow to equilibrate; dilute to 1000.0 mL with water R and mix again.
Flow rate 1 mL/min.
Detection Spectrophotometer at 254 nm.
Injection 20 µL of test solution (a) and reference solutions (a), (b) and (c).
Run time 4 times the retention time of hydrocortisone acetate.
Identification of impurities Use the chromatogram supplied with hydrocortisone acetate for peak identification CRS and the chromatogram obtained with reference solution (c) to identify the peaks due to impurities A, B, D, E and G; use the chromatogram obtained with reference solution (a) to identify the peak due to impurity C.
Relative retention With reference to hydrocortisone acetate (retention time = about 10 min): impurity A = about 0.4; impurity B = about 0.7; impurity C = about 0.9; impurity D = about 1.2; impurity G = about 1.8; impurity E = about 2.3.
Loss on drying (2.2.32)
Maximum 0.5 per cent, determined on 1.000 g by drying in vacuo at 60 °C for 3 h.
ASSAY
Liquid chromatography (2.2.29) as described in the test for related substances with the following modifications.
Injection Test solution (b) and reference solution (d).
Run time 1.5 times the retention time of hydrocortisone acetate.
Retention time Hydrocortisone acetate = about 10 min.
Calculate the percentage content of C23H32O6 taking into account the assigned content of hydrocortisone acetate CRS.
STORAGE
Protected from light.
IMPURITIES
Specified impurities A, B, C, D, E, G
Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use): F.
Ph Eur